Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 386(16), P. 1532 - 1546

Published: March 2, 2022

A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome 2 highly vaccinated populations has aroused concerns about effectiveness current vaccines.

Language: Английский

---

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Nature, Journal Year: 2021, Volume and Issue: 596(7871), P. 276 - 280

Published: July 8, 2021

Language: Английский

---

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

New England Journal of Medicine, Journal Year: 2021, Volume and Issue: 385(16), P. 1474 - 1484

Published: July 28, 2021

BackgroundDespite the high efficacy of BNT162b2 messenger RNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough infections have been reported, including among health care workers. Data are needed to characterize these and define correlates infectivity.MethodsAt largest medical center in Israel, we identified by performing extensive evaluations workers who were symptomatic (including mild symptoms) or had known infection exposure. These included epidemiologic investigations, repeat reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays, antigen-detecting rapid diagnostic testing (Ag-RDT), serologic genomic sequencing. Correlates assessed a case–control analysis. We matched patients with antibody titers obtained within week before SARS-CoV-2 detection (peri-infection period) four five uninfected controls used generalized estimating equations predict geometric mean cases ratio between two groups. also correlation neutralizing N gene cycle threshold (Ct) values respect infectivity.Download PDF Research Summary.ResultsAmong 1497 fully vaccinated for whom RT-PCR data available, 39 documented. Neutralizing case during peri-infection period lower than those (case-to-control ratio, 0.361; 95% confidence interval, 0.165 0.787). Higher associated infectivity (higher Ct values). Most asymptomatic, although 19% persistent symptoms (>6 weeks). The B.1.1.7 (alpha) variant was found 85% samples tested. A total 74% viral load (Ct value, <30) at some point their infection; however, patients, only 17 (59%) positive result on concurrent Ag-RDT. No secondary documented.ConclusionsAmong workers, occurrence correlated period. did occur. Quick Take Covid-19 Vaccinated Health Care Workers 1m 58s

Language: Английский

---

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

The Lancet, Journal Year: 2021, Volume and Issue: 398(10309), P. 1407 - 1416

Published: Oct. 1, 2021

Language: Английский

---

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

New England Journal of Medicine, Journal Year: 2021, Volume and Issue: 385(15), P. 1393 - 1400

Published: Sept. 15, 2021

On July 30, 2021, the administration of a third (booster) dose BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) was approved in Israel for persons who were 60 years age or older and had received second at least 5 months earlier. Data are needed regarding effect booster on rate confirmed coronavirus 2019 disease (Covid-19) severe illness.We extracted data period from 30 through August 31, Israeli Ministry Health database 1,137,804 been fully vaccinated (i.e., two doses BNT162b2) In primary analysis, we compared Covid-19 illness between those injection 12 days earlier (booster group) not (nonbooster group). secondary evaluated infection 4 to 6 after as with booster. all analyses, used Poisson regression adjusting possible confounding factors.At dose, lower group than nonbooster by factor 11.3 (95% confidence interval [CI], 10.4 12.3); 19.5 CI, 12.9 29.5). vaccination 5.4 4.8 6.1).In this study involving participants earlier, found that rates substantially among (third) vaccine.

Language: Английский

---

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Nature Medicine, Journal Year: 2021, Volume and Issue: 27(11), P. 2032 - 2040

Published: Sept. 29, 2021

Abstract The global supply of COVID-19 vaccines remains limited. An understanding the immune response that is predictive protection could facilitate rapid licensure new vaccines. Data from a randomized efficacy trial ChAdOx1 nCoV-19 (AZD1222) vaccine in United Kingdom was analyzed to determine antibody levels associated with against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after second dose were measured infected noninfected recipients. Higher all markers correlated reduced risk symptomatic infection. A 80% infection majority Alpha (B.1.1.7) variant SARS-CoV-2 achieved 264 (95% CI: 108, 806) binding units (BAU)/ml: 506 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike anti-RBD antibodies, 26 NC, NC) international unit (IU)/ml 247 101, normalized neutralization titers (NF 50 ) pseudovirus live-virus neutralization, respectively. Immune asymptomatic infections 5% significance level. These can be used bridge populations using validated assays, allow extrapolation estimates

Language: Английский

---

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Nature, Journal Year: 2021, Volume and Issue: 602(7898), P. 664 - 670

Published: Dec. 23, 2021

Language: Английский

---

The T cell immune response against SARS-CoV-2

Nature Immunology, Journal Year: 2022, Volume and Issue: 23(2), P. 186 - 193

Published: Feb. 1, 2022

Language: Английский

---

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

The Lancet, Journal Year: 2022, Volume and Issue: 399(10328), P. 924 - 944

Published: Feb. 23, 2022

Knowing whether COVID-19 vaccine effectiveness wanes is crucial for informing policy, such as the need and timing of booster doses. We aimed to systematically review evidence duration protection vaccines against various clinical outcomes, assess changes in rates breakthrough infection caused by delta variant with increasing time since vaccination.

Language: Английский

---

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Nature, Journal Year: 2021, Volume and Issue: 602(7898), P. 654 - 656

Published: Dec. 23, 2021

Abstract The emergence of the SARS-CoV-2 variant concern Omicron (Pango lineage B.1.1.529), first identified in Botswana and South Africa, may compromise vaccine effectiveness lead to re-infections 1 . Here we investigated escape from neutralization by antibodies African individuals vaccinated with Pfizer BNT162b2. We used blood samples taken soon after vaccination who were previously infected or no evidence previous infection. isolated sequence-confirmed live virus an person observed that requires angiotensin-converting enzyme 2 (ACE2) receptor infect cells. compared plasma relative ancestral strain found was much higher vaccinated-only participants. However, both groups showed a 22-fold reduction vaccine-elicited variant. Participants had been exhibited residual similar level vaccination-only group. These data support notion reasonable protection against be maintained using approaches.

Language: Английский

---